Symbols

KALV

KalVista·NASDAQ

--(--)

KALV fundamentals

KALV Q3 2025 Earnings

KalVista (KALV) released its earnings on Nov 10, 2025: revenue was 13.69M (YoY --), missed estimates; EPS was -0.92 (YoY 0.00%), missed estimates.

Revenue / YoY

13.69M

EPS / YoY

-0.92

0.00%

Report date

Nov 10, 2025

KALV Earnings Call Summary for Q3,2025

Breakout Launch: 937 start forms in 3 months, with 50% of adopters being high-burden patients (≥2 attacks/month) achieving 1-2 cartons/month refill rates.
Financial Strength: $13.7M in Q3 sales, fully funded through profitability with $150M convertible notes.
Global Momentum: Commercial launches in Germany and Japan (Q1 2026), with U.K. NICE discussions advancing.
Clinical Validation: 84% patient satisfaction among switchers; KONFIDENT-KID trial validates EKTERLY's efficacy in children (0.8 attacks/month).

Earnings

EPS

Revenue

Revenue & Expenses

KALV has released its 2026 Q1 earnings report, with revenue of 1.43M, reflecting a YoY change of NaN%, and net profit of -60.10M, showing a YoY change of -48.59%. The Sankey diagram below clearly presents KALV's revenue sources and cost distribution.

Key Indicators

KalVista (KALV) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

KalVista (KALV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

KalVista (KALV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

KalVista (KALV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown